Skip to Main Content

Nurix Therapeutics, Inc. Common stock

NRIX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
NRIX Income Statement
NRIX Balance Sheet
NRIX Cash Flow

Recent trades of NRIX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
NRIX Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
NRIX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
NRIX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quarterly net insider trading by NRIX's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Cbl inhibitors and compositions for use in adoptive cell therapy Oct. 22, 2024
  • Patent Title: Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof Sep. 17, 2024
  • Patent Title: Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof Jul. 30, 2024
  • Patent Title: Combination therapies with cbl-b inhibitor compounds Jun. 25, 2024
  • Patent Title: 3-substituted piperidine compounds for cbl-b inhibition, and use thereof Apr. 09, 2024
  • Patent Title: Bifunctional compounds for degrading btk via ubiquitin proteosome pathway Jan. 09, 2024
  • Patent Title: Bifunctional compounds for degrading btk via ubiquitin proteosome pathway Nov. 21, 2023
  • Patent Title: Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof Aug. 29, 2023
  • Patent Title: Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof Dec. 20, 2022
  • Patent Title: Bifunctional compounds for degrading btk via ubiquitin proteosome pathway Oct. 25, 2022
  • Patent Title: 3-substituted piperidine compounds for cbl-b inhibition, and use thereof Oct. 11, 2022
  • Patent Title: Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof Aug. 02, 2022
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of NRIX in WallStreetBets Daily Discussion

NRIX News

Recent insights relating to NRIX

CNBC Recommendations

Recent picks made for NRIX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in NRIX

NRIX Top Shareholders
Shareholder
Shares Held
NRIX Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

NRIX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view NRIX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top